NL-OMON22574已完成不适用
A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, 3-Period, Crossover Study to Investigate the Effects of Ethanol and L-000830982 on Essential Tremor.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Men and women;
- •2. At least 18 years of age;
排除标准
- •1. Medical condition interfering with clinical evaluations or conduct of the study;
- •2. Smoking > 5 cigarettes per day;
研究者
相似试验
尚未招募
不适用
Pharmacological effects on nerve excitability in healthy volunteers•PainNL-OMON25429•Centre for Human Drug Research, Leiden18
进行中（未招募）
不适用
A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients with Chronic Obstructive Pulmonary Disease (COPD).MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDChronic Obstructive Pulmonary DiseaseEUCTR2008-001933-84-CZBoehringer Ingelheim RCV GmbH & Co KG1,150
进行中（未招募）
不适用
A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients with Chronic Obstructive Pulmonary Disease (COPD).Chronic Obstructive Pulmonary DiseaseMedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-001934-28-SEBoehringer Ingelheim AB860
进行中（未招募）
不适用
A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients with Chronic Obstructive Pulmonary Disease (COPD).Chronic Obstructive Pulmonary DiseaseMedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-001934-28-DKBoehringer Ingelheim Denmark860
进行中（未招募）
不适用
A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients with Chronic Obstructive Pulmonary Disease (COPD).MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDChronic Obstructive Pulmonary DiseaseEUCTR2008-001933-84-DKBoehringer Ingelheim Danmark A/S860